Osteoprotegerin ELISA Kit

Catalog No. ABIN456063

Product Details Osteoprotegerin ELISA Kit

Target: Osteoprotegerin (TNFRSF11B) (Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B))

Reactivity: Mouse

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Detection Range: 7.8-500 pg/mL

Minimum Detection Limit: 7.8 pg/mL

Application: ELISA

Purpose: This immunoassay kit allows for the in vitro quantitative determination of mouse Osteoprotegerin, OPG concentrations in serum, plasma and other biological fluids.

Sample Type: Plasma, Serum

Analytical Method: Quantitative

Specificity: This assay recognizes recombinant and natural mouse OPG.

Cross-Reactivity (Details): No significant cross-reactivity or interference was observed.

Sensitivity: < 3.9 pg/mL
The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest detectable concentration that could be differentiated from zero.

Characteristics: Mus musculus,Mouse,Tumor necrosis factor receptor superfamily member 11B,Osteoclastogenesis inhibitory factor,Osteoprotegerin,Tnfrsf11b,Ocif,Opg

Application Details

Sample Volume: 100 μL

Plate: Pre-coated

Protocol: The microtiter plate provided in this kit has been pre-coated with an antibody specific to OPG. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for OPG and Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then a TMB substrate solution is added to each well. Only those wells that contain OPG, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of OPG in the samples is then determined by comparing the O.D. of the samples to the standard curve. 2

Restrictions: For Research Use only

Handling

Storage: 4 °C/-20 °C

Storage Comment: The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 °C upon being received. The other reagents can be stored at 4 °C.

Target Details for Osteoprotegerin

Target: Osteoprotegerin (TNFRSF11B) (Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B))

Alternative Name: Tnfrsf11b (TNFRSF11B Products)

Synonyms: CD254 ELISA Kit, ODF ELISA Kit, OPGL ELISA Kit, OPTB2 ELISA Kit, RANKL ELISA Kit, TRANCE ELISA Kit, hRANKL2 ELISA Kit, sOdf ELISA Kit, OCIF ELISA Kit, OPG ELISA Kit, TR1 ELISA Kit, Opg ELISA Kit, ocif ELISA Kit, opg ELISA Kit, tr1 ELISA Kit, TNF superfamily member 11 ELISA Kit, TNF receptor superfamily member 11b ELISA Kit, tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) ELISA Kit, TNF receptor superfamily member 11B ELISA Kit, tumor necrosis factor receptor superfamily member 11b S homeolog ELISA Kit, tumor necrosis factor receptor superfamily, member 11b ELISA Kit, TNFSF11 ELISA Kit, TNFRSF11B ELISA Kit, Tnfrsf11b ELISA Kit, tnfrsf11b.S ELISA Kit

Target Type: Chemical

Background: Osteoprotegerin, also known as osteoclastogenesis inhibitory factor (OCIF), is a cytokine and a member of the tumor necrosis factor (TNF) receptor superfamily. It is a basic glycoprotein comprising 401 amino acid residues arranged into 7 structural domains. It is found as either a 60 kDa monomer or 120 kDa dimer linked by disulfide bonds.Osteoprotegerin inhibits the differentiation of macrophages into osteoclasts and also regulates the resorption of osteoclasts in vitro and in vivo. Osteoprotegerin is a RANK homolog, and works by binding to RANK ligand on osteoblast/stromal cells, thus blocking the RANK-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast. Recombinant human osteoprotegerin specifically acts on bone, increasing bone mineral density and bone volume. Osteoprotegerin has been used experimentally to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases. Osteoprotegerin production is stimulated in vivo by the female sex hormone estrogen,as well as the experimental osteoporosis drug, strontium ranelate.